- Home
- ADAG vs ASRT Comparison
ADAG vs ASRT Comparison
Compare ADAG & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADAG | ASRT |
|---|---|---|
| Founded | 2011 | 1995 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.8M | 75.1M |
| IPO Year | 2021 | 1997 |
Fundamental Metrics
Financial Performance| Metric | ADAG | ASRT |
|---|---|---|
| Price | $1.93 | $0.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $8.00 | $3.00 |
| AVG Volume (30 Days) | 73.7K | ★ 356.0K |
| Earning Date | 08-12-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $103,204.00 | ★ $137,354,000.00 |
| Revenue This Year | $6,983.06 | N/A |
| Revenue Next Year | $36.05 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 9.22 |
| 52 Week Low | $1.30 | $0.51 |
| 52 Week High | $3.16 | $1.01 |
Technical Indicators
Market Signals| Indicator | ADAG | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 49.37 | 32.28 |
| Support Level | $1.76 | $0.70 |
| Resistance Level | $1.90 | $0.75 |
| Average True Range (ATR) | 0.15 | 0.04 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 53.19 | 13.68 |
Price Performance
Historical ComparisonAbout ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.